Skip to main content
Watch Insiders
GLUEHealthcare

Monte Rosa Therapeutics Inc (GLUE) Insider Trading

In the last 90 days, 1 Monte Rosa Therapeutics Inc (GLUE) insider reported no open-market purchases and 1 sale totaling $137.28. Source: SEC Form 4 filings.

SEC-reported filing activity is provided for research purposes and is not investment advice.

90-day C-suite buyers
0
90-day purchase value
$0.00
Corporate buyers
0
Latest transaction
Oct 5, 2026

Executive filings

Open-market transaction history

Purchase and sale summaries are ordered by the latest reported transaction date.

Open-market insider purchase and sale transactions
DateInsider nameRoleTypeSharesPriceTotal value
Oct 5, 2026Matthew BowenPrincipal Accounting OfficerSale13$10.56$137.28
Jul 16, 2026Markus WarmuthPresident & CEOSale9,500$23.18$220,219
Jul 15, 2026Jennifer ChampouxChief Operating OfficerSale4,351$23.38$101,730
Jul 6, 2026Sharon TownsonChief Scientific OfficerSale6,000$23.31$139,849
Jun 30, 2026Filip JankuChief Medical OfficerSale5,407$24.50$132,472
Jun 29, 2026Filip JankuChief Medical OfficerSale6,000$22.95$137,700
Jun 29, 2026Anthony M. ManningDirectorSale10,000$23.11$231,100
Jun 24, 2026Filip JankuChief Medical OfficerSale41,845$21.08$882,201
Jun 23, 2026Sharon TownsonChief Scientific OfficerSale3,000$20.00$60,000
Jun 23, 2026Jennifer ChampouxChief Operating OfficerSale2,175$20.00$43,500
🔒 Create Free Insider Alerts — Join Watch Insiders

Common questions

GLUE insider trading FAQ

Are GLUE insiders buying or selling?
Over the last 90 days, GLUE insiders were net sellers, reporting $0.00 of open-market purchases and $137.28 of sales.
When was the last GLUE insider purchase?
No open-market insider purchase of Monte Rosa Therapeutics Inc stock was reported in the last 90 days.
Where does GLUE insider trading data come from?
Watch Insiders reads the SEC Form 4 filings that Monte Rosa Therapeutics Inc officers, directors, and 10% owners submit to EDGAR, and refreshes this page daily.